{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T17:37:54Z","timestamp":1793641074694,"version":"4.5.1"},"reference-count":77,"publisher":"BMJ","issue":"3","license":[{"start":{"date-parts":[[2021,3,18]],"date-time":"2021-03-18T00:00:00Z","timestamp":1616025600000},"content-version":"unspecified","delay-in-days":17,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2021,1,26]]},"published-print":{"date-parts":[[2021,3]]},"abstract":"<jats:p>Cancer patients are highly vulnerable to SARS-CoV-2 infections due to frequent contacts with the healthcare system, immunocompromised state from cancer or its therapies, supportive medications such as steroids and most importantly their advanced age and comorbidities. Patients with lung cancer have consistently been reported to suffer from an increased risk of death compared with other cancers. This is possibly due to the combination of specific pathophysiological aspects, including underlying pulmonary compromise due to smoking history and the increased specific pressures on respiratory healthcare services caused by the related pandemic. Rationally and safely treating patients with lung cancer during the pandemic has become a continuous challenge over the last year. Deciding whether to offer, modify, postpone or even cancel treatments for this particular patient\u2019s population has become the crucial recurrent dilemma for lung cancer professionals. Chemotherapy, immunotherapy and targeted agents represent distinct risks factors in the context of COVID-19 that should be balanced with the short-term and long-term consequences of delaying cancer care. Despite the rapid and persistent trend of the pandemic, declared by WHO on March 11, 2020, and still ongoing at the time of writing (January 2021), various efforts were made by oncologists worldwide to understand the impact of COVID-19 on patients with cancer. Adapted recommendations of our evidence-based practice guidelines have been developed for all stakeholders. Different small and large-scale registries, such as the COVID-19 and Cancer Consortium (CCC19) and Thoracic Cancers International COVID-19 Collaboration quickly collected data, supporting cancer care decisions under the challenging circumstance created by the COVID-19 pandemic. Several recommendations were developed as guidance for prioritizing the various aspects of lung cancer care in order to mitigate the adverse effects of the COVID-19 healthcare crisis, potentially reducing the morbidity and mortality of our patients from COVID-19 and from cancer. These recommendations helped inform decisions about treatment of established disease, continuation of clinical research and lung cancer screening. In this review, we summarize available evidence regarding the direct and indirect impact of the COVID-19 pandemic on lung cancer care and patients.<\/jats:p>","DOI":"10.1136\/jitc-2020-002266","type":"journal-article","created":{"date-parts":[[2021,3,18]],"date-time":"2021-03-18T13:06:58Z","timestamp":1616072818000},"page":"e002266","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":105,"title":["Severity of COVID-19 in patients with lung cancer: evidence and challenges"],"prefix":"10.1136","volume":"9","clinical-trial-number":[{"clinical-trial-number":"nct04538456","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7575-3870","authenticated-orcid":false,"given":"Antonio","family":"Passaro","sequence":"first","affiliation":[{"name":"Division of Thoracic Oncology, European Institute of Oncology IRCCS, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Bestvina","sequence":"additional","affiliation":[{"name":"Department of Hematology\/Oncology, University of Chicago Medicine, Chicago, Illinois, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Velez Velez","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, David Geffen School of Medicine, University of California, Los Angeles, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina Chiara","family":"Garassino","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward","family":"Garon","sequence":"additional","affiliation":[{"name":"David Geffen School of Medicine, UCLA, University of California Los Angeles, Los Angeles, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Solange","family":"Peters","sequence":"additional","affiliation":[{"name":"Department of Oncology, Centre Hospitalier Universitaire Vaudois, CHUV, Lausanne, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2021,3,18]]},"reference":[{"key":"2025100300445107000_9.3.e002266.1","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/j.ccell.2020.09.018","article-title":"COVID-19 and cancer: current challenges and perspectives","volume":"38","author":"Bakouny","year":"2020","journal-title":"Cancer Cell"},{"key":"2025100300445107000_9.3.e002266.2","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1016\/j.annonc.2020.03.296","article-title":"Clinical characteristics of COVID-19-infected cancer patients: a retrospective case study in three hospitals within Wuhan, China","volume":"31","author":"Zhang","year":"2020","journal-title":"Ann Oncol"},{"key":"2025100300445107000_9.3.e002266.3","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.ejca.2020.08.011","article-title":"Mortality in patients with cancer and coronavirus disease 2019: a systematic review and pooled analysis of 52 studies","volume":"139","author":"Saini","year":"2020","journal-title":"Eur J Cancer"},{"key":"2025100300445107000_9.3.e002266.4","doi-asserted-by":"crossref","first-page":"S992","DOI":"10.1016\/j.annonc.2020.08.1735","article-title":"1670O prospective data of first 1,797 hospitalised patients with cancer and COVID-19 derived from the COVID-19 clinical information network and international severe acute respiratory and emerging infections Consortium, who coronavirus clinical characterisation Consortium","volume":"31","author":"Palmieri","year":"2020","journal-title":"Ann Oncol"},{"key":"2025100300445107000_9.3.e002266.5","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)31187-9"},{"key":"2025100300445107000_9.3.e002266.6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41571-020-00441-5","article-title":"COVID-19 in patients with cancer: managing a pandemic within a pandemic","volume":"18","author":"Horn","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"key":"2025100300445107000_9.3.e002266.7","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1016\/j.annonc.2020.04.002","article-title":"Testing for COVID-19 in lung cancer patients","volume":"31","author":"Passaro","year":"2020","journal-title":"Ann Oncol"},{"key":"2025100300445107000_9.3.e002266.8","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30096-6"},{"key":"2025100300445107000_9.3.e002266.9","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1001\/jamaoncol.2020.0980","article-title":"SARS-CoV-2 transmission in patients with cancer at a tertiary care hospital in Wuhan, China","volume":"6","author":"Yu","year":"2020","journal-title":"JAMA Oncol"},{"key":"2025100300445107000_9.3.e002266.10","doi-asserted-by":"publisher","DOI":"10.1002\/path.5241"},{"key":"2025100300445107000_9.3.e002266.11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2015432"},{"key":"2025100300445107000_9.3.e002266.12","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1016\/S2213-2600(20)30239-3","article-title":"Tobacco smoking and COVID-19 infection","volume":"8","author":"van Zyl-Smit","year":"2020","journal-title":"Lancet Respir Med"},{"key":"2025100300445107000_9.3.e002266.13","doi-asserted-by":"crossref","DOI":"10.1016\/S2213-2600(20)30117-X","article-title":"Sex difference and smoking predisposition in patients with COVID-19","volume":"8","author":"Cai","year":"2020","journal-title":"Lancet Respir Med"},{"key":"2025100300445107000_9.3.e002266.14","doi-asserted-by":"publisher","DOI":"10.18332\/tid\/119324"},{"key":"2025100300445107000_9.3.e002266.15","unstructured":"LYW L , Cazier JB , Starkey T . COVID-19 prevalence and mortality in patients with cancer and the effect of primary tumour subtype and patient demographics: a prospective cohort study. Lancet Oncol 2020;2020."},{"key":"2025100300445107000_9.3.e002266.16","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30388-0"},{"key":"2025100300445107000_9.3.e002266.17","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-20-0596"},{"key":"2025100300445107000_9.3.e002266.18","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.ccell.2020.07.006","article-title":"Cancer patients and risk of mortality for COVID-19","volume":"38","author":"Curigliano","year":"2020","journal-title":"Cancer Cell"},{"key":"2025100300445107000_9.3.e002266.19","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1016\/S1470-2045(20)30309-0","article-title":"Clinical characteristics and risk factors associated with COVID-19 disease severity in patients with cancer in Wuhan, China: a multicentre, retrospective, cohort study","volume":"21","author":"Tian","year":"2020","journal-title":"Lancet Oncol"},{"key":"2025100300445107000_9.3.e002266.20","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-20-0422"},{"key":"2025100300445107000_9.3.e002266.21","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1038\/s43018-020-0104-9","article-title":"SARS-CoV-2 infection in the Italian Veneto region: adverse outcomes in patients with cancer","volume":"1","author":"Rugge","year":"2020","journal-title":"Nat Cancer"},{"key":"2025100300445107000_9.3.e002266.22","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2020.09.027","article-title":"Dutch oncology COVID-19 Consortium: outcome of COVID-19 in patients with cancer in a nationwide cohort study","volume":"141","author":"de Joode","year":"2020","journal-title":"Eur J Cancer"},{"key":"2025100300445107000_9.3.e002266.23","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1016\/S1470-2045(20)30442-3","article-title":"COVID-19 prevalence and mortality in patients with cancer and the effect of primary tumour subtype and patient demographics: a prospective cohort study","volume":"21","author":"Lee","year":"2020","journal-title":"Lancet Oncol"},{"key":"2025100300445107000_9.3.e002266.24","doi-asserted-by":"crossref","first-page":"Abstract nr IA26","DOI":"10.1158\/1557-3265.COVID-19-IA26","article-title":"Understanding the impact of COVID in cancer patients through the COVID-19 and Cancer (CCC-19) and other COVID consortiums [abstract]. In: Proceedings of the AACR Virtual Meeting: COVID-19 and Cancer; 2020 Jul 20-22. Philadelphia (PA): AACR","volume":"26","author":"Rini","year":"2020","journal-title":"Clin Cancer Res"},{"key":"2025100300445107000_9.3.e002266.25","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2020.38.18_suppl.LBA110","article-title":"Clinical impact of COVID-19 on patients with cancer: data from the COVID-19 and cancer Consortium (CCC19)","volume":"38","author":"Warner","year":"2020","journal-title":"J Clin Oncol"},{"key":"2025100300445107000_9.3.e002266.26","doi-asserted-by":"crossref","first-page":"S1202","DOI":"10.1016\/j.annonc.2020.08.2313","article-title":"LBA72 assessment of clinical and laboratory prognostic factors in patients with cancer and SARS-CoV-2 infection: the COVID-19 and cancer Consortium (CCC19)","volume":"31","author":"Grivas","year":"2020","journal-title":"Ann Oncol"},{"key":"2025100300445107000_9.3.e002266.27","doi-asserted-by":"crossref","first-page":"S0923-7534(20)39894-X","DOI":"10.1016\/j.annonc.2020.06.007","article-title":"COVID-19 in patients with lung cancer","volume":"31","author":"Luo","year":"2020","journal-title":"Ann Oncol"},{"key":"2025100300445107000_9.3.e002266.28","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1016\/S1470-2045(20)30314-4","article-title":"COVID-19 in patients with thoracic malignancies (TERAVOLT): first results of an international, registry-based, cohort study","volume":"21","author":"Garassino","year":"2020","journal-title":"Lancet Oncol"},{"key":"2025100300445107000_9.3.e002266.29","doi-asserted-by":"crossref","first-page":"S1204","DOI":"10.1016\/j.annonc.2020.08.2316","article-title":"LBA75 defining COVID-19 outcomes in thoracic cancer patients: TERAVOLT (thoracic cancERs international coVid 19 collaboration)","volume":"31","author":"Baena Espinar","year":"2020","journal-title":"Annals of Oncology"},{"key":"2025100300445107000_9.3.e002266.30","doi-asserted-by":"crossref","unstructured":"Horn L , Whisenant JG , Torri V . Thoracic cancers international COVID-19 collaboration (TERAVOLT): impact of type of cancer therapy and COVID therapy on survival. Journal of Clinical Oncology;38.","DOI":"10.1200\/JCO.2020.38.18_suppl.LBA111"},{"key":"2025100300445107000_9.3.e002266.31","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2020.01777","article-title":"Outcomes of COVID-19 in patients with lung cancer treated in a tertiary hospital in Madrid","volume":"10","author":"Calles","year":"2020","journal-title":"Front Oncol"},{"key":"2025100300445107000_9.3.e002266.32","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1016\/j.jtho.2020.05.001","article-title":"Treatment guidance for patients with lung cancer during the coronavirus 2019 pandemic","volume":"15","author":"Dingemans","year":"2020","journal-title":"J Thorac Oncol"},{"key":"2025100300445107000_9.3.e002266.33","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1200\/OP.20.00286","article-title":"Management of lung cancer during the COVID-19 pandemic","volume":"16","author":"Singh","year":"2020","journal-title":"JCO Oncol Pract"},{"key":"2025100300445107000_9.3.e002266.34","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1016\/j.annonc.2020.07.010","article-title":"Managing cancer patients during the COVID-19 pandemic: an ESMO multidisciplinary expert consensus","volume":"31","author":"Curigliano","year":"2020","journal-title":"Ann Oncol"},{"key":"2025100300445107000_9.3.e002266.35","doi-asserted-by":"publisher","DOI":"10.1136\/esmoopen-2020-000820"},{"key":"2025100300445107000_9.3.e002266.36","doi-asserted-by":"crossref","first-page":"100331","DOI":"10.1016\/j.eclinm.2020.100331","article-title":"Clinical characteristics and outcomes of patients undergoing surgeries during the incubation period of COVID-19 infection","volume":"21","author":"Lei","year":"2020","journal-title":"EClinicalMedicine"},{"key":"2025100300445107000_9.3.e002266.37","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S0140-6736(20)31182-X","article-title":"Mortality and pulmonary complications in patients undergoing surgery with perioperative SARS-CoV-2 infection: an international cohort study","volume":"396","year":"2020","journal-title":"Lancet"},{"key":"2025100300445107000_9.3.e002266.38","doi-asserted-by":"crossref","DOI":"10.1016\/S1470-2045(20)30691-4","article-title":"Lung cancer control in the UK hit badly by COVID-19 pandemic","volume":"21","author":"Gourd","year":"2020","journal-title":"Lancet Oncol"},{"key":"2025100300445107000_9.3.e002266.39","unstructured":"United Kingdom Lung Cancer Coalition . COVID-19 Matters. Available: https:\/\/www.uklcc.org.uk\/wp-content\/uploads\/2020\/10\/UKLCC-COVID-19-Matters-Report-Oct-2020.pdf [Accessed 10 Dec 2020]."},{"key":"2025100300445107000_9.3.e002266.40","unstructured":"American Society of Oncology . COVID-19 patient care information. Available: https:\/\/www.asco.org\/asco-coronavirusinformation\/care-individuals-cancer-during-covid-19 [Accessed 10 Dec 2020]."},{"key":"2025100300445107000_9.3.e002266.41","unstructured":"American College of Surgeons . 2020 COVID-19 guidelines for triage of thoracic patients. Available: https:\/\/www.facs.org\/covid-19\/clinical-guidance\/elective-case\/thoracic-cancer [Accessed 10 Dec 2020]."},{"key":"2025100300445107000_9.3.e002266.42","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.radonc.2020.04.001","article-title":"Practice recommendations for lung cancer radiotherapy during the COVID-19 pandemic: an ESTRO-ASTRO consensus statement","volume":"146","author":"Guckenberger","year":"2020","journal-title":"Radiother Oncol"},{"key":"2025100300445107000_9.3.e002266.43","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1016\/j.jtho.2020.04.016","article-title":"Alternative multidisciplinary management options for locally advanced NSCLC during the coronavirus disease 2019 global pandemic","volume":"15","author":"Kumar","year":"2020","journal-title":"J Thorac Oncol"},{"key":"2025100300445107000_9.3.e002266.44","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.lungcan.2020.05.029","article-title":"Optimizing lung cancer radiation treatment worldwide in COVID-19 outbreak","volume":"146","author":"Liao","year":"2020","journal-title":"Lung Cancer"},{"key":"2025100300445107000_9.3.e002266.45","doi-asserted-by":"crossref","unstructured":"Wise-Draper TM . Systemic cancer treatment-related outcomes in patients with SARS-CoV-2 infection: a CCC19 registry analysis. ESMO 2020.","DOI":"10.1016\/j.annonc.2020.08.2312"},{"key":"2025100300445107000_9.3.e002266.46","unstructured":"Center for Disease Control . Duration of Isolation & Precautions for Adults. Available: https:\/\/www.cdc.gov\/coronavirus\/2019-ncov\/hcp\/duration-isolation.html [Accessed 10 Dec 2020]."},{"key":"2025100300445107000_9.3.e002266.47","doi-asserted-by":"crossref","first-page":"m4087","DOI":"10.1136\/bmj.m4087","article-title":"Mortality due to cancer treatment delay: systematic review and meta-analysis","volume":"4","author":"Hanna","year":"2020","journal-title":"BMJ"},{"key":"2025100300445107000_9.3.e002266.48","doi-asserted-by":"crossref","first-page":"269","DOI":"10.2217\/imt-2020-0067","article-title":"Controversies about COVID-19 and anticancer treatment with immune checkpoint inhibitors","volume":"12","author":"Bersanelli","year":"2020","journal-title":"Immunotherapy"},{"key":"2025100300445107000_9.3.e002266.49","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2020.2493","article-title":"Weight-based dosing of pembrolizumab every 6 weeks in the time of COVID-19","author":"Goldstein","year":"2020","journal-title":"JAMA Oncol"},{"key":"2025100300445107000_9.3.e002266.50","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.annonc.2019.10.015","article-title":"Model-based evaluation of the efficacy and safety of nivolumab once every 4 weeks across multiple tumor types","volume":"31","author":"Zhao","year":"2020","journal-title":"Ann Oncol"},{"key":"2025100300445107000_9.3.e002266.51","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1007\/s00280-019-03954-8","article-title":"Alternative dosing regimens for atezolizumab: an example of model-informed drug development in the postmarketing setting","volume":"84","author":"Morrissey","year":"2019","journal-title":"Cancer Chemother Pharmacol"},{"key":"2025100300445107000_9.3.e002266.52","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)32222-6"},{"key":"2025100300445107000_9.3.e002266.53","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/S2213-2600(20)30170-3","article-title":"Challenges in lung cancer therapy during the COVID-19 pandemic","volume":"8","author":"Calabr\u00f2","year":"2020","journal-title":"Lancet Respir Med"},{"key":"2025100300445107000_9.3.e002266.54","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-20-0823"},{"key":"2025100300445107000_9.3.e002266.55","unstructured":"Medidata . The impact of COVID-19 on clinical trial sites. Available: https:\/\/www.medidata.com\/wp-content\/uploads\/2020\/09\/COVID19-Response9.0_Clinical-Trials_2020921_v2.pdf"},{"key":"2025100300445107000_9.3.e002266.56","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2020.103120","article-title":"Implications of COVID-19 pandemic on lung cancer management: a multidisciplinary perspective","volume":"156","author":"Bakhribah","year":"2020","journal-title":"Crit Rev Oncol Hematol"},{"key":"2025100300445107000_9.3.e002266.57","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/j.ccell.2020.04.003","article-title":"Cancer research after COVID-19: where do we go from here?","volume":"37","author":"Colbert","year":"2020","journal-title":"Cancer Cell"},{"key":"2025100300445107000_9.3.e002266.58","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.21037\/tlcr-20-594","article-title":"Challenges and issues surrounding the use for translational research of human samples obtained during the COVID-19 pandemic from lung cancer patients","volume":"9","author":"Hofman","year":"2020","journal-title":"Transl Lung Cancer Res"},{"key":"2025100300445107000_9.3.e002266.59","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30388-0"},{"key":"2025100300445107000_9.3.e002266.60","doi-asserted-by":"crossref","first-page":"3373","DOI":"10.21037\/apm-20-1662","article-title":"The impact of the COVID-19 pandemic on lung cancer patients","volume":"9","author":"Sha","year":"2020","journal-title":"Ann Palliat Med"},{"key":"2025100300445107000_9.3.e002266.61","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1016\/j.ccell.2020.05.007","article-title":"NCI\u2019s work to advance cancer research while responding to the COVID-19 pandemic","volume":"37","author":"Singer","year":"2020","journal-title":"Cancer Cell"},{"key":"2025100300445107000_9.3.e002266.62","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1038\/d41573-020-00093-1","article-title":"Impact of COVID-19 on oncology clinical trials","volume":"19","author":"Upadhaya","year":"2020","journal-title":"Nat Rev Drug Discov"},{"key":"2025100300445107000_9.3.e002266.63","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2020.103120","article-title":"Implications of COVID-19 pandemic on lung cancer management: a multidisciplinary perspective","volume":"156","author":"Bakhribah","year":"2020","journal-title":"Crit Rev Oncol Hematol"},{"key":"2025100300445107000_9.3.e002266.64","doi-asserted-by":"crossref","unstructured":"Webster P . How is biomedical research funding faring during the COVID-19 lockdown? Nat Med 2020.doi:10.1038\/d41591-020-00010-4","DOI":"10.1038\/d41591-020-00010-4"},{"key":"2025100300445107000_9.3.e002266.65","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1001\/jamaoncol.2020.5403","article-title":"Integrated survival estimates for cancer treatment delay among adults with cancer during the COVID-19 pandemic","volume":"6","author":"Hartman","year":"2020","journal-title":"JAMA Oncol"},{"key":"2025100300445107000_9.3.e002266.66","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.2217\/fon-2020-0397","article-title":"The future of cancer research after COVID-19 pandemic: recession?","volume":"16","author":"Kourie","year":"2020","journal-title":"Future Oncol"},{"key":"2025100300445107000_9.3.e002266.67","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-ND2020-006"},{"key":"2025100300445107000_9.3.e002266.68","doi-asserted-by":"crossref","first-page":"6141","DOI":"10.1002\/cam4.3292","article-title":"COVID-19 pandemic and impact on cancer clinical trials: an academic medical center perspective","volume":"9","author":"Marcum","year":"2020","journal-title":"Cancer Med"},{"key":"2025100300445107000_9.3.e002266.69","article-title":"The impact of COVID-19 on clinical trial execution at the Dana-Farber cancer Institute","volume":"382","author":"Tolaney","year":"2020","journal-title":"J Natl Cancer Inst"},{"key":"2025100300445107000_9.3.e002266.70","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1200\/OP.20.00275","article-title":"Early impact of COVID-19 on the conduct of oncology clinical trials and long-term opportunities for transformation: findings from an American Society of clinical oncology survey","volume":"16","author":"Waterhouse","year":"2020","journal-title":"JCO Oncol Pract"},{"key":"2025100300445107000_9.3.e002266.71","unstructured":"FDA guidance on conduct of clinical trials of medical products during the COVID-19 public health emergency. 9\/2020, 2020. Available: https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/fda-guidance-conduct-clinical-trials-medical-products-during-covid-19-public-health-emergency [Accessed 1 Dec 2020]."},{"key":"2025100300445107000_9.3.e002266.72","unstructured":"Guidance on the management of clinical trials during the COVID-19 (coronavirus) pandemic, 2020. Available: https:\/\/ec.europa.eu\/health\/sites\/health\/files\/files\/eudralex\/vol-10\/guidanceclinicaltrials_covid19_en.pdf [Accessed 3 Dec 2020]."},{"key":"2025100300445107000_9.3.e002266.73","article-title":"Priority COVID-19 vaccination for patients with cancer while vaccine supply is limited","author":"Ribas","year":"2020","journal-title":"Cancer Discov"},{"key":"2025100300445107000_9.3.e002266.74","unstructured":"ASCO COVID-19 Vaccine & Patients with Cancer. Available: https:\/\/www.asco.org\/asco-coronavirus-resources\/covid-19-patient-care-information\/covid-19-vaccine-patients-cancer [Accessed 24 Jan 2021]."},{"key":"2025100300445107000_9.3.e002266.75","unstructured":"ESMO statements for vaccination against COVID-19 in patients with cancer. Available: https:\/\/www.esmo.org\/covid-19-and-cancer\/covid-19-vaccination [Accessed 24 Jan 2021]."},{"key":"2025100300445107000_9.3.e002266.76","unstructured":"NCCN new guidance principles for vaccinating people with cancer against COVID-19. Available: https:\/\/www.nccn.org\/about\/news\/newsinfo.aspx?NewsID=2552 [Accessed 24 Jan 2021]."},{"key":"2025100300445107000_9.3.e002266.77","unstructured":"SITC statement on SARS-CoV-2 vaccination and cancer immunotherapy. Available: https:\/\/www.sitcancer.org\/aboutsitc\/press-releases\/2020\/sitc-statement-sars-cov-2-vaccination-cancer-immunotherapy [Accessed 24 Jan 2021]."}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2020-002266","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T07:45:13Z","timestamp":1759477513000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2020-002266"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3]]},"references-count":77,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2021,3,18]]},"published-print":{"date-parts":[[2021,3]]}},"alternative-id":["10.1136\/jitc-2020-002266"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2020-002266","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3]]}}}